

S 3080

Cancer Drug Parity Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Oct 27, 2021

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Oct 27, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/senate-bill/3080>

Sponsor

Name: Sen. Smith, Tina [D-MN]

Party: Democratic • **State:** MN • **Chamber:** Senate

Cosponsors (21 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Baldwin, Tammy [D-WI]	D · WI		Oct 27, 2021
Sen. Blumenthal, Richard [D-CT]	D · CT		Oct 27, 2021
Sen. Boozman, John [R-AR]	R · AR		Oct 27, 2021
Sen. Brown, Sherrod [D-OH]	D · OH		Oct 27, 2021
Sen. Capito, Shelley Moore [R-WV]	R · WV		Oct 27, 2021
Sen. Collins, Susan M. [R-ME]	R · ME		Oct 27, 2021
Sen. Cramer, Kevin [R-ND]	R · ND		Oct 27, 2021
Sen. Hyde-Smith, Cindy [R-MS]	R · MS		Oct 27, 2021
Sen. Klobuchar, Amy [D-MN]	D · MN		Oct 27, 2021
Sen. Markey, Edward J. [D-MA]	D · MA		Oct 27, 2021
Sen. Merkley, Jeff [D-OR]	D · OR		Oct 27, 2021
Sen. Moran, Jerry [R-KS]	R · KS		Oct 27, 2021
Sen. Murphy, Christopher [D-CT]	D · CT		Oct 27, 2021
Sen. Scott, Rick [R-FL]	R · FL		Oct 27, 2021
Sen. Whitehouse, Sheldon [D-RI]	D · RI		Oct 27, 2021
Sen. Wicker, Roger F. [R-MS]	R · MS		Oct 27, 2021
Sen. Murkowski, Lisa [R-AK]	R · AK		Nov 17, 2021
Sen. Feinstein, Dianne [D-CA]	D · CA		Dec 9, 2021
Sen. Reed, Jack [D-RI]	D · RI		Dec 17, 2021
Sen. Tester, Jon [D-MT]	D · MT		Apr 26, 2022
Sen. King, Angus S., Jr. [I-ME]	I · ME		Sep 29, 2022

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Oct 27, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 HR 4385	Identical bill	Jul 9, 2021: Referred to the House Committee on Education and Labor.

Summary (as of Oct 27, 2021)

Cancer Drug Parity Act of 2021

This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Actions Timeline

- **Oct 27, 2021:** Introduced in Senate
- **Oct 27, 2021:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.